1. Volume 67, Issue 1, Pages 278-284 (January 2005)
B-type natriuretic peptide for acute dyspnea in patients with kidney disease: Insights from a randomized comparison 
Christian Mueller, Kirsten Laule-Kilian, Andra Scholer, Charly Nusbaumer, Thomas Zeller, Daniel Staub, Andra P. Perruchoud, Dr 
Kidney International 
Volume 67, Issue 1, Pages (January 2005)
DOI: /j x
Copyright © 2005 International Society of Nephrology Terms and Conditions

2. Figure 1
Cumulative frequency distribution curve displaying the time to discharge of patients with or without kidney disease in the B-type natriuretic peptide (BNP) group versus the control group. BNP testing exclusively reduced the time to discharge in patients without kidney disease.
Kidney International  , DOI: ( /j x)
Copyright © 2005 International Society of Nephrology Terms and Conditions

3. Figure 2
Total treatment cost in the control group versus the B-type natriuretic peptide (BNP) group in patients with and without kidney disease. BNP testing exclusively reduced total treatment cost in patients without kidney disease. Boxes show means and I bars represent 95% confidence intervals.
Kidney International  , DOI: ( /j x)
Copyright © 2005 International Society of Nephrology Terms and Conditions